MYELODYSPLASTIC SYNDROMES (MDS)
Clinical trials for MYELODYSPLASTIC SYNDROMES (MDS) explained in plain language.
Never miss a new study
Get alerted when new MYELODYSPLASTIC SYNDROMES (MDS) trials appear
Sign up with your email to follow new studies for MYELODYSPLASTIC SYNDROMES (MDS), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Supercharged immune cells take on hard-to-treat blood cancers
Disease control Recruiting nowThis study tests whether giving specially engineered natural killer (NK) cells from donated cord blood, along with chemotherapy, is safe and effective for people with relapsed or hard-to-treat blood cancers like leukemia, lymphoma, and multiple myeloma. About 80 participants will…
Matched conditions: MYELODYSPLASTIC SYNDROMES (MDS)
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 16, 2026 12:57 UTC
-
New cord blood transplant method could boost survival in tough blood cancers
Disease control Recruiting nowThis study is testing an improved method for cord blood transplants in adults with high-risk blood cancers like leukemia and lymphoma. The approach includes a standard chemotherapy and radiation plan, a specific number of stem cells, and careful follow-up. Researchers want to see…
Matched conditions: MYELODYSPLASTIC SYNDROMES (MDS)
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 16, 2026 12:49 UTC
-
Engineered immune cells take on tough blood cancers in early trial
Disease control Recruiting nowThis early-phase trial tests a personalized cell therapy called CART123 for adults with certain blood cancers (like acute myeloid leukemia) that have not responded to standard treatments. Each patient's own immune cells are collected, modified to target the CD123 protein on cance…
Matched conditions: MYELODYSPLASTIC SYNDROMES (MDS)
Phase: EARLY_PHASE1 • Sponsor: Institute of Hematology and Blood Transfusion, Czech Republic • Aim: Disease control
Last updated Jun 16, 2026 12:48 UTC
-
New drug could help High-Risk patients get Life-Saving transplants
Disease control Recruiting nowThis early-phase study tests whether Darzalex Faspro can safely lower donor-specific antibodies (DSAs) in 8 adults with blood cancers or bone marrow failure who are at high risk of rejecting a stem cell transplant. The goal is to reduce DSA levels enough to allow the transplant t…
Matched conditions: MYELODYSPLASTIC SYNDROMES (MDS)
Phase: EARLY_PHASE1 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated Jun 15, 2026 19:05 UTC
-
New drug cocktail aims to make risky stem cell transplants safer for blood cancer patients
Disease control Recruiting nowThis study is for people with high-risk blood cancers (like AML or MDS) who need a stem cell transplant from a partially matched donor. The goal is to see if a new combination of two drugs, bendamustine and cyclophosphamide, can reduce serious side effects like graft-versus-host …
Matched conditions: MYELODYSPLASTIC SYNDROMES (MDS)
Phase: PHASE2 • Sponsor: St. Petersburg State Pavlov Medical University • Aim: Disease control
Last updated Jun 15, 2026 19:04 UTC
-
New hope for rare bone marrow cancer: targeted pill vs standard chemo
Disease control Recruiting nowThis study is for adults with a bone marrow disorder called MDS that has a specific gene change (IDH1 mutation) and who have not had a certain type of treatment before. The goal is to see if a daily pill (ivosidenib) works better than a standard injection (azacitidine) at control…
Matched conditions: MYELODYSPLASTIC SYNDROMES (MDS)
Phase: PHASE3 • Sponsor: Institut de Recherches Internationales Servier • Aim: Disease control
Last updated Jun 12, 2026 12:04 UTC
-
New hope for leukemia patients? early trial launches
Disease control Recruiting nowThis early-phase study tests a new drug (ICP-248) combined with a standard medicine (azacitidine) in people with acute myeloid leukemia or myelodysplastic syndromes. The goal is to find a safe dose and see if the combo helps control the disease. About 266 adults who have not resp…
Matched conditions: MYELODYSPLASTIC SYNDROMES (MDS)
Phase: PHASE1 • Sponsor: Beijing InnoCare Pharma Tech Co., Ltd. • Aim: Disease control
Last updated Jun 11, 2026 11:57 UTC
-
Blood disorder drug luspatercept under Long-Term safety review
Disease control Recruiting nowThis study looks at the long-term safety of luspatercept in people with certain blood disorders (MDS, beta-thalassemia, or myelofibrosis) who were in earlier luspatercept trials. Participants either continue treatment or enter long-term follow-up to monitor side effects, disease …
Matched conditions: MYELODYSPLASTIC SYNDROMES (MDS)
Phase: PHASE3 • Sponsor: Celgene • Aim: Disease control
Last updated Jun 09, 2026 12:07 UTC